EUVIMEDEUVIMED entdecken
Open Access

Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline

Nadia Howlader iD, Huann-Sheng Chen iD, Anne-Michelle Noone, Daniel Miller, Jeffry Byrne, Serban Negoita iD, Kathleen A Cronin, Angela B Mariotto

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Nadia Howlader und 7 weiteren Autor:innen. Beteiligte Einrichtung: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Surveillance Research Program, Division of Cancer Control and Population Sciences, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic led to substantial declines in cancer incidence rates in 2020, likely because of disruptions in screening and diagnostic services. This study aimed to assess the impact of the pandemic on cancer incidence rates in the United States using 2021 incidence data from the Surveillance, Epidemiology, and End Results program. The analysis compared observed 2021 cancer incidence rates with expected prepandemic trends, evaluating changes by individual cancer site and stage. Although incidence overall and in many cancer sites the rates were close to prepandemic levels, they did not exhibit a recovery that incorporated the delayed diagnoses from 2020. There were exceptions, however, such as metastatic breast cancer, which showed significantly higher observed rates than expected (rate ratio = 1.09, 95% confidence interval = 1.04 to 1.13). Ongoing monitoring and targeted interventions are needed to address the long-term consequences of the COVID-19 pandemic on cancer care and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansIncidenceUnited StatesSEER ProgramFemaleSARS-CoV-2MaleMiddle Aged

Autor:innen und Institutionen

  • Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
  • Information Management Services, Calverton, MD, USA.

ORCID-Profile: Nadia Howlader, Huann-Sheng Chen, Serban Negoita

Förderung

  • Surveillance Research Program
  • Division of Cancer Control and Population Sciences
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Howlader, N., Chen, H. S., Noone, A. M., Miller, D., Byrne, J., Negoita, S., Cronin, K. A., & Mariotto, A. B. (2025). Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae180

Vancouver

Howlader N, Chen HS, Noone AM, Miller D, Byrne J, Negoita S, et al. Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae180

BibTeX
@article{Howlader2025,
  author = {Howlader, Nadia and Chen, Huann-Sheng and Noone, Anne-Michelle and Miller, Daniel and Byrne, Jeffry and Negoita, Serban and Cronin, Kathleen A and Mariotto, Angela B},
  title = {Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae180}
}
Kostenlos starten →